Kyverna (KYTX) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential derivative action claims on behalf of shareholders of Kyverna Therapeutics, Inc. (“Kyverna Therapeutics” or the “Company”) (KYTX) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

What's Being Investigated?

The inquiry follows the filing of a class action complaint on December 9, 2024, which alleges that Kyverna Therapeutics made false and misleading statements in connection with its initial public offering on February 8, 2024. According to the complaint, the Company was in possession of adverse data related to one of its ongoing clinical trials prior to the IPO. It is alleged that this adverse data negatively impacted Kyverna Therapeutics’s lead product and rendered the trends and results disclosed in the offering documents misleading.

According to the complaint, the Company’s risk-factor and MD&A disclosures were deficient under Items 105 and 303, rendering the IPO Offering Documents misleading. When the market learned the alleged truth, investors suffered significant damages.

On June 14, 2024, Kyverna presented KYV-101 data at EULAR and published an investor presentation disclosing adverse data; by filing, shares traded as low as $3.92 (>82% below the $22 IPO price).

Why Shareholders Are Concerned?

The investigation seeks to determine whether the board of directors and executive officers of Kyverna Therapeutics failed to implement and monitor effective disclosure controls and oversight mechanisms regarding the integrity of clinical trial data. The investigation also concerns whether certain directors and officers may have disregarded red flags or failed to act in good faith in connection with the Company’s public disclosures, particularly as they relate to mission-critical risks such as clinical safety and data integrity. The potential for conflicts of interest and the adequacy of board-level review of risk disclosures are also under scrutiny.

What Shareholders Can Do?

If you have held Kyverna Therapeutics, Inc. (KYTX) stock since at least February 2024, you may be able to seek corporate reforms, the return of funds to Kyverna, and a court-approved incentive award for you, all at absolutely no cost.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.